The nonobese diabetic (NOD) mouse has been developed as a model for insulin-dependent diabetes. One gene required for the development of diabetes is associated with the major histocompatibility complex. This gene possibly could be linked to class II genes, which show a unique pattern in NOD mice. To evaluate the role of the I-A class II antigen expressed in NOD mice, we studied the effect of anti-I-A monoclonal antibodies on disease onset in vivo. Long-term treatment with anti-class II IgG2a antibodies specific for NOD I-A antigen prevented the spontaneous development of diabetes, as opposed to control antibodies shown not to react with NOD I-A antigen. Anti-class II antibodies apparently elicited active immune suppression, requiring a fully immunocompetent host, rather than passive blockade of class II antigen. Treatment with anti-class II antibody effectively prevented the adoptive transfer of diabetes produced by splenocytes from diabetic NOD mice into newborn mice but failed to prevent adoptive transfer into irradiated adult NOD recipients. Direct evidence for the induction of suppressor cells was obtained from the passive transfer of spleen cells from anti-class II antibody-treated NOD donors. The injection of anti-class II antibody-treated spleen cells collected from NOD donors prevented the development of diabetes, which normally follows transfer of diabetogenic spleen cells into irradiated 8-week-old male NOD recipients. Depletion experiments indicate that CD41 cells are responsible for anti-class II-induced protection transferred by spleen cells.
The nonobese diabetic (NOD) mouse has been introduced as a model for insulin-dependent diabetes mellitus (IDDM) (1) . Spontaneous diabetes is observed from postnatal week 12 and occurs primarily in females. IDDM can be induced earlier in males and in females by administration of cyclophosphamide (2) . The role of autoimmunity against pancreatic islet beta cells is indicated in this model by the presence of mononuclear cell infiltration of the islets of Langerhans prior to development of diabetes (3) and by prevention of insulitis and/or IDDM after neonatal thymectomy (4), anti-L3T4 monoclonal antibody (mAb) treatment (5, 6) , or administration of cyclosporine A (7). In addition, adoptive transfer of overt diabetes from diabetic NOD mice into healthy neonates depends exclusively on T lymphocytes (8) .
Genetic studies have shown a polygenic basis for susceptibility to IDDM in the NOD model. One genetic component maps to the major histocompatibility complex (MHC) of this inbred strain (9, 10) . The NOD mouse expresses a unique class II antigen encoded by the I-A locus (H-2I region), which is similar to I-Ad except for the first external domain of the ,8 chain. Five consecutive nucleotide substitutions on I-A p chain lead to two amino acid changes located in positions 56 and 57 (11) . A similar substitution in position 57 of the external domain of the HLA-DQ ,3 chain has been correlated with the development of IDDM in man (12) .
Antisera and mAbs to class II MHC antigens have been shown to alter various immune functions in vitro, including antigen presentation to T cells. Moreover, such antibodies can suppress antibody production in vivo (13) . Autoimmune diseases associated with class II MHC antigens also have been prevented by in vivo administration of anti-class II mAbs (14) (15) (16) (17) . Spontaneous IDDM has been prevented in BB rats by an antibody directed against the I-E equivalent of rat class II antigen (18) . The prevention of autoimmune diseases by anti-class II mAb treatment has obvious potential therapeutic implications. Moreover, it provides a tool for studying the functional role of MHC antigens in the development of autoimmune reactions in vivo. In the present study, we show the prevention of spontaneous IDDM in female NOD mice by administration of mAbs to I-A antigens. Using adoptive transfer experiments in vivo, we present experimental evidence indicating that this protective effect is mediated through the action of suppressor L3T4+ T lymphocytes.
MATERIALS AND METHODS
Mice. NOD mice were bred in our facilities under specific pathogen-free conditions and were checked every 6 months for multiple bacterial, viral, and parasitic infections because infections have been suspected to interfere with diabetes development. The spontaneous incidence of diabetes in our colony reached 42.5% in females and 1.2% in males by postnatal week 34. No diabetes was observed in our colony in males by postnatal week 20. Nude Swiss, DBA/2 (H-2d), and CBA (1-2k) mice were purchased from Iffa Credo (L'Arbresle, France).
Monitoring of Mice. In all experiments, mice were monitored for glycosuria three times a week (Glukotest, Boehringer Mannheim). Glycosuric mice (and all mice at the end of each experimental procedure) were checked for fasting glycemia by using test strips and a colorimetric assay (Haemoglucotest and Reflolux F, Boehringer Mannheim). Diabetes was diagnosed when permanent fasting glycemia > 3 g/liter occurred.
mAbs. Hybridoma lines 10-3-6 (19), 10-2-16 (19) , MKD6 (20) , and 14-4-4 (21) (provided by H. 0. McDevitt, Stanford University, Stanford, CA) were grown as ascites in nude Swiss mice. 10-3-6 and 10-2-16 mAbs are specific for IAf k r u s (Ia-17), whereas MKD6 mAb is directed against I-Ad, and 14-4-4 mAb is specific for I-Ek d p r. The four mAbs, all of IgG2a isotype, were purified by precipitation with 40% (vol/vol) saturated ammonium sulfate, followed by protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) affinity chromatography. Eluted antibodies were dialyzed for 24 hr against phosphate-buffered saline (PBS) and stored at -70°C at a concentration of 2 mg/ml. The specificity of the mAbs Proc. Natl. Acad. Sci. USA 85 (1988) was assessed in a RIA as described (22 developed IDDM, as opposed to 5 of the 11 mice treated with MKD6 ( Fig. 1 ), indicating that anti-class II mAb treatment prevented spontaneous IDDM in female mice. Histopathology performed at 34 weeks of age on sections from nondiabetic animals did not show any significant difference between both groups. The incidence of insulitis was 12 of 14 in treated animals and 4 of 6 in control animals.
In the second experiment, instead of initiating anti-class II mAb treatment from birth, mice were treated from neonatal week 3 to week 34 with either 10-2-16 or 14-4-4 mAb. As in the first experiment, strong protection against the development of spontaneous IDDM was obtained by anti-class II antibody treatment. Only 1 of the 31 animals developed IDDM during 10-2-16 mAb treatment, whereas 9 of the 32 animals in the control group injected with anti-I-E mAb became diabetic (Fig. 2) (Fig. 3) .
In the second experiment, the action of anti-class II mAbs was evaluated on adoptively transferred 8-week-old irradiated NOD male recipients. These recipients were treated from birth to postnatal week 20 with either 10-3-6 or MKD6 mAbs. In contrast to the protection of adoptively transferred NOD neonates, anti-class II mAb treatment of irradiated adult recipients provided no protection against the transfer of diabetes. Five of six animals developed IDDM when treated with 10-3-6 mAb, as compared with seven of eight recipients treated with MKD6 mAb (Fig. 4) .
Role with either 10-3-6 or MKD6 mAb. These two groups were divided into two subgroups each, one group receiving injections of the same mAb as that injected in the corresponding donor of spleen cells up to the end of the experiment and the other group receiving no further treatment. All of these animals were adoptively transferred with diabetogenic spleen cells. Protection by anti-class II mAb treatment was restored by injection of spleen cells from 10-3-6 mAb-treated donors in the groups where 10-3-6 mAb treatment was maintained in the recipient animals. In contrast, protection against adoptive transfer of diabetes was not observed in irradiated male recipients restored with lymphoid cells from MKD6 mAbtreated donors or in the recipient groups restored with lymphoid cells from 10-3-6 mAb-treated mice without further injection of 10-3-6 ( Table 2) .
Protection Passively Transferred by Spleen Cells Is Mediated by T Lymphocytes. To evaluate the role of T lymphocytes from anti-class II mAb-treated animals and to determine whether T cell-depleted spleen cells could still restore the protection against diabetes transfer, we performed the same experimental design as described in the previous experiment using T cell-depleted spleen cells from 10-3-6 mAb-treated donors. In the first experiment, irradiated male recipients were injected with 10-3-6 mAb-treated spleen cells, either total (treated in vitro with complement alone) or T celldepleted (treated in vitro with 4221 antibody plus complement) collected from 12-day-old NOD mice treated from birth with 10-3-6 mAb. All recipient animals were adoptively transferred with diabetogenic spleen cells and subsequently ' 34. Numbers in parentheses are as in Fig. 1 . The difference in the incidence of spontaneous diabetes between the experimental and the control groups was statistically significant (P < 0.025).
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( Fig. 1 . The difference in the incidence of successful transfer between the experimental and the control groups was statistically significant (P < 0.01).
were treated with 10-3-6 mAb. Eleven of 13 animals injected with T cell-depleted 10-3-6-treated spleen cells became diabetic after the transfer of diabetogenic spleen cells. In contrast, only 2 of 9 animals that received nondepleted 10-3-6-treated spleen cells developed IDDM after the transfer of diabetogenic spleen cells. Ten of 11 recipients that received non-T-cell-depleted MKD6-treated spleen cells from 12-day-old donors as control, and MKD6 mAb antibody thereafter, developed IDDM (Fig. 5) .
In the second experiment, irradiated male recipients were injected with either total (treated in vitro with complement alone), Lyt2-depleted (treated with 3.155 mAb plus complement), or L3T4-depleted (treated with 172.4 mAb plus complement) spleen cells collected from 1-month-old NOD mice treated from birth with 10-3-6 mAb. All animals were adoptively transferred with diabetogenic spleen cells and subsequently treated with 10-3-6 mAb. Eight of the 10 animals injected with the L3T4-depleted spleen cells became diabetic after the transfer of diabetogenic spleen cells. In contrast, only 1 of 9 animals that received Lyt2-depleted spleen cells developed IDDM by postnatal week 16, and none of 10 animals that received total spleen cells developed IDDM. All 10 control animals that received no protective spleen cells but were treated with 10-3-6 mAb starting 1 day after transfer of diabetogenic spleen cells developed IDDM (Fig. 6) . (24) , and allograft rejection (25) (26) (27) . On the basis of these observations, anti-class II mAbs have been used to prevent the development of several autoimmune diseases, including experimental allergic encephalomyelitis (14) , experimental myasthenia gravis (15), the spontaneous lupus syndrome of (NZB x NZW)F1 mice (16), type II collagen arthritis in mice (17) , and spontaneous IDDM in BB rats (18) . The present work extends the previous demonstration with BB rats that anti-class II antibodies protect against autoimmune IDDM to the NOD mouse model. The two IgG2a mAbs that share the same specificity (Ia-17) reacted with NOD I-A antigen and prevented spontaneous diabetes in NOD female mice as opposed to control IgG2a anti-class II mAbs. The absence of prevention of insulitis was not unexpected because histological infiltration of the islet does not necessarily preclude the development of IDDM in NOD mice.
We also have studied the effect of anti-I-A mAb treatment on animals that were adoptively transferred with diabetogenic spleen cells. Disease transfer into NOD neonates or irradiated adult recipients has been shown to depend on T lymphocytes, including both Lyt2+ and L3T4+ subsets (8, 28) . Prevention of diabetes induction in NOD healthy recipients thus indicates that the protection induced by anti-class II mAb is still effective on committed T cells mediating passive transfer. In contrast, anti-class II antibody treatment failed to prevent passive transfer of diabetes into irradiated male NOD recipients.
It was hypothesized that irradiation was the reason for the failure of anti-class II mAb to confer protection in the adult transfer model. The Fig. 1 . A statistically significant difference in the incidence of diabetes transfer was observed between animals injected with total spleen cells or Lyt2-depleted cells and animals injected with L3T4-depleted cells (P < 0.001 in both comparisons).
Proc. Natl. Acad. Sci. USA 85 (1988) vitro in models of active immunization against tumor, viral, or allogeneic antigens. A xenoantiserum to nonpolymorphic determinants of class II molecules has been shown to render radiosensitive T lymphocytes capable of inhibiting influenza virus-specific human T-cell clone proliferation in vitro (29) and immunoglobulin production after pokeweed mitogen stimulation (30) .
Similarly, in vivo treatment with relevant antisera or mAbs to class II antigens has been shown to elicit the emergence of spleen T lymphocytes capable of transferring suppression of delayed-type hypersensitivity reactions (26, 27, 31, 32) . In the case of delayed-type hypersensitivity response to tumor antigens, the T lymphocytes responsible for transferring suppression were shown to be sensitive to a low dose of cyclophosphamide (31) . Taken together, these observations and the findings that we report in NOD mice suggest that induction of suppressor T lymphocytes is an important mechanism determining the immunosuppression elicited by anti-class II antibody treatment in vivo. However, the activation of suppressor T cells is only secondary, and anti-class II antibodies act primarily at a different level of the immune system. Evidence has been presented in vitro to suggest that a direct effect on antigen-presenting cells may be the first step of anti-class II mAb action in a model studying the action of anti-Ia mAb on the response of primed T cells to sperm whale myoglobulin in the presence of untreated macrophages in vitro (33) . The possibility of multiple actions on antigen presentation and secondarily on immunoregulatory T lymphocytes should be investigated in vivo.
In vivo anti-class II antibody treatment in the neonatal period has been shown to abrogate directly antigen presentation to T lymphocytes primed with foreign antigen or alloantigen (24) . In addition, treatment in the neonatal period with anti-class II mAbs induces the disappearance of I-A-and I-E-bearing cells (34) and the alteration of T-cell development, including absence of Lyt2-L3T4' T cells both in thymus and the periphery (35) . It has been suggested that the reduction of L3T4' cells is secondary to the effect of anti-class II antibody on antigen-presenting cells (35, 36) . Interestingly, modifications of lymphocyte populations by anti-class II mAbs were transient and reverted upon cessation of treatment (35, 36) .
Our data in NOD mice point to different mechanisms of action of anti-I-A. We also have observed a decrease of I-A expression and L3T4' spleen cells in NOD mice treated from birth (data not shown), but these manifestations are transient, although the treatment was maintained, and seem to be independent of the protection against diabetes. L3T4' cells appear to be responsible for transferring the protection in our model. The same protective effect on spontaneous IDDM was observed irrespective of whether anti-class II treatment was started at birth or at neonatal week 3.
Other mechanisms of action of anti-class II mAb treatment in vivo should also be considered. A depletion of B lymphocytes and a comodulation of I-A and I-E antigens on B-cell membranes have been reported upon anti-I-A or -I-E antibody treatment in vivo (37, 38) . The significance of these B-cell modifications in the inhibition of the immune response developed against autoantigen remains unknown. A direct action of anti-class II antibody treatment on pancreatic islets is to be considered as well but remains unclear because aberrant expression of class II antigens on islet beta cells is controversial in the NOD mouse model (39, 40) . The specificity of the protection induced by anti-Ia antibodies in regard to the antigen used for immunizing spleen cell donors has been suggested in the case of immunization against tumoral antigens (33) and delayed-type hypersensitivity to alloantigens (28) . The 
